EUVIMEDOpdag EUVIMED
FallberichtOpen access

Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design

Ashley Dunford iD, Stefania Yee iD, Jennifer J Thomas iD, Kamryn T Eddy iD, Esther Dechant iD

European Eating Disorders Review · 2026

DOI: 10.1002/erv.70135 ↗

At a glance

Fallbericht in European Eating Disorders Review, 2026. Written by Ashley Dunford and 4 co-authors. Institution: Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA. Major MEDLINE topics: Binge-Eating Disorder, Cognitive Behavioral Therapy, Gastric Inhibitory Polypeptide. 14 references. The full text is freely available in PubMed Central. Funded by: NIMH NIH HHS, NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Many patients with larger bodies present to eating disorder (ED) treatment seeking weight loss. Whether glucose‐dependent insulinotropic polypeptide/glucagon‐like‐peptide receptor agonists (GIP/GLP‐1s) are helpful or harmful for such patients remains unknown. This single case experimental design study examined the effects of Tirzepatide (7.5 mg/0.05 mL), a GIP/GLP‐1 following 10‐session cognitive‐behavioural therapy (CBT‐T) in a patient with binge‐eating disorder (BED) and obesity.

Method

A 37‐year‐old female presented to an outpatient ED clinic with BED and a body mass index of 68.9 kg/m 2 . We assessed weekly and then monthly ED behaviours and cognitions using the Eating Disorder 15 (ED‐15) across two treatment phases: CBT‐T (3 months) and GIP/GLP‐1 administration (9 months).

Results

As hypothesised, ED cognitions and binge frequency decreased during CBT‐T. Also as hypothesised, during GIP/GLP‐1 phase, binge frequency remained low and dietary restraint absent. We observed continued reductions in ED cognitions and 39‐pound weight loss.

Discussion

GIP/GLP‐1 treatment after CBT‐T was followed by ED remission and weight loss without serious adverse events. CBT‐T skills may mitigate risk of disordered eating during GIP/GLP‐1 use. The combination of psychotherapy and GIP/GLP‐1s may further reduce binge‐eating and lead to weight loss. Research is needed to explore risks and benefits of GIP/GLP‐1s for patients with EDs.

Subjects

MeSH terms (MEDLINE)

Binge-Eating DisorderCognitive Behavioral TherapyGastric Inhibitory PolypeptideHumansFemaleAdultTirzepatideCombined Modality TherapyTreatment OutcomeObesity

Author keywords

GIP/GLP‐1binge eatingbinge‐eating disordercognitive–behavioural therapyfeeding and eating disorderglucose‐dependent insulinotropic polypeptide/glucagon‐like‐peptide receptor ago…higher weightlarger bodyobesitysingle‐case experiment

Substances

TirzepatideGastric Inhibitory Polypeptide

Authors and institutions

  • Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Mass General Brigham Multidisciplinary Eating Disorders Research Collaborative, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID profiles: Ashley Dunford, Stefania Yee, Jennifer J Thomas, Kamryn T Eddy, Esther Dechant

Funding

  • NIMH NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Dunford, A., Yee, S., Thomas, J. J., Eddy, K. T., & Dechant, E. (2026). Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design. European Eating Disorders Review. https://doi.org/10.1002/erv.70135

Vancouver

Dunford A, Yee S, Thomas JJ, Eddy KT, Dechant E. Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design. European Eating Disorders Review. 2026. doi:10.1002/erv.70135

BibTeX
@article{Dunford2026,
  author = {Dunford, Ashley and Yee, Stefania and Thomas, Jennifer J and Eddy, Kamryn T and Dechant, Esther},
  title = {Glucose‐Dependent Insulinotropic Polypeptide/Glucagon‐Like‐Peptide‐1 Use Following 10‐Session Cognitive–Behavioural Therapy for Binge‐Eating Disorder: A Single‐Case Experimental Design},
  journal = {European Eating Disorders Review},
  year = {2026},
  doi = {10.1002/erv.70135}
}
Start for free →